Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics, Inc.
Abeona Therapeutics, Inc. ABEO | 0.00 |
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).